Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib-Reference-Cited by-同舟云学术

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib

Published:2020-03 Issue: Volume:141 Page:114-118
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zhao Jun,Lin Gen^ORCID,Zhuo Minglei,Fan Zaiwen,Miao Liyun,Chen Likun,Zeng Aiping,Yin Rong,Ou Yangming,Shi Zhihui,Yin Jie,Gao Wen,Chen Jianhua,Zhou Xiangdong,Zeng Yong,Liu Xiang,Xu Huamin^ORCID,Chen Rongrong,Xia Xuefeng,Carbone David P.^ORCID

Funder

National Key Research and Development Program of China

Joint Funds for the Innovation of Science and Technology, Fujian province, China

Fujian Provincial Health and Family Research Talent training program, Fujian province, China

Science and Technology Department guided projects, Fujian province, China

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov.,2014

2. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib;Oxnard;JAMA Oncol.,2018

3. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib;Ou;Lung Cancer,2017

4. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib;Callegari;Chem. Sci.,2018

5. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers;Blakely;Nat. Genet.,2017

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds;Cell Communication and Signaling;2024-07-26

2. Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study;2024-06-11

3. Superficial fibromas with CTNNB1 mutation;Genes, Chromosomes and Cancer;2024-05

4. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer;JTO Clinical and Research Reports;2024-04

5. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04